增强不确定性下的成本效益分析：对价值评估的影响——理论依据与实证支持
Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value Assessment-Rationale and Empirical Support.
作者信息
Garrison Louis P, Zamora Bernarda, Li Meng, Towse Adrian
机构信息
The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, University of Washington, Seattle.
Office of Health Economics, London, United Kingdom.
出版信息
J Manag Care Spec Pharm. 2020 Apr;26(4):400-406. doi: 10.18553/jmcp.2020.26.4.400.
Abstract
This study received unrestricted funding from the Pharmaceutical Research Manufacturers of America. The authors also do consulting, personally or through their employment, with numerous pharmaceutical manufacturers, payers, and other stakeholders with a general interest in this subject matter.
摘要
本研究获得了美国制药研究与制造商协会的无限制资金。作者个人或通过其所在机构，还为众多制药商、支付方以及其他对该主题普遍感兴趣的利益相关者提供咨询服务。
相似文献
1
Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value Assessment-Rationale and Empirical Support.增强不确定性下的成本效益分析：对价值评估的影响——理论依据与实证支持
J Manag Care Spec Pharm. 2020 Apr;26(4):400-406. doi: 10.18553/jmcp.2020.26.4.400.
2
Examining Misaligned Incentives for Payers and Manufacturers in Value-Based Pharmaceutical Contracts.审视基于价值的药品合同中支付方和制药商的利益错位。
J Manag Care Spec Pharm. 2020 Jan;26(1):63-66. doi: 10.18553/jmcp.2020.26.1.63.
3
Reflections on the ISPOR Special Task Force on U.S. Value Frameworks: Implications of a Health Economics Approach for Managed Care Pharmacy.关于 ISPOR 特别工作组对美国价值框架的思考：健康经济学方法对管理式医疗药学的影响。
J Manag Care Spec Pharm. 2019 Nov;25(11):1185-1192. doi: 10.18553/jmcp.2019.25.11.1185.
4
Employer and Plan Sponsor Views on Pharmacy Reimbursement.雇主和计划发起人对药房报销的看法。
J Manag Care Spec Pharm. 2020 Jun;26(6):710-712. doi: 10.18553/jmcp.2020.26.6.710.
5
Tailoring access to high cost, genetically targeted drugs.定制高成本基因靶向药物的获取方式。
Med J Aust. 2005 Jun 20;182(12):607-8. doi: 10.5694/j.1326-5377.2005.tb06844.x.
6
Use of randomized controlled trials in organizational decision making: a cost-minimization approach.随机对照试验在组织决策中的应用：一种成本最小化方法。
Am J Manag Care. 2000 Aug;6(8):894-904.
7
Assessment of the Quality of the Clinical Evidence in Submissions to the Australian Pharmaceutical Benefits Advisory Committee: Fit for Purpose?提交给澳大利亚药品福利咨询委员会的材料中临床证据质量的评估：是否符合目的？
Value Health. 2015 Jun;18(4):467-76. doi: 10.1016/j.jval.2015.02.011. Epub 2015 Apr 11.
8
Should national pharmacare apply a value-based insurance design?国家药物保险计划是否应采用基于价值的保险设计？
CMAJ. 2019 Jul 22;191(29):E811-E815. doi: 10.1503/cmaj.181721.
9
Using the Delphi method to identify meaningful and feasible outcomes for pharmaceutical value-based contracting.运用德尔菲法确定药品价值型合同有意义且可行的结果。
J Manag Care Spec Pharm. 2020 Nov;26(11):1385-1389. doi: 10.18553/jmcp.2020.26.11.1385.
10
Value-Based Pricing for Emerging Gene Therapies: The Economic Case for a Higher Cost-Effectiveness Threshold.新兴基因疗法的基于价值的定价：更高成本效益阈值的经济学案例。
J Manag Care Spec Pharm. 2019 Jul;25(7):793-799. doi: 10.18553/jmcp.2019.18378. Epub 2019 Feb 20.
引用本文的文献
1
Reflecting Social Values in HTA Methods: A Case Study of South Africa.卫生技术评估方法中反映的社会价值观：以南非为例的研究。
Appl Health Econ Health Policy. 2025 Jul 14. doi: 10.1007/s40258-025-00990-9.
2
Defining the value proposition in diagnostic technology: challenges and opportunities for its understanding and development - a review with a multiperspective reflective analysis.界定诊断技术中的价值主张：理解与发展所面临的挑战和机遇——一项多视角反思性分析综述
Front Med (Lausanne). 2025 Feb 20;12:1498618. doi: 10.3389/fmed.2025.1498618. eCollection 2025.
3
Health Equity Considerations in Cost-Effectiveness Analysis: Insights from an Umbrella Review.成本效益分析中的健康公平考量：一项系统性综述的见解
Clinicoecon Outcomes Res. 2024 Aug 20;16:581-596. doi: 10.2147/CEOR.S471827. eCollection 2024.
4
Val (EU) xit: do we need an international ISPOR value flower?瓦尔（欧盟）xit：我们需要一朵国际药物经济学与结果研究协会（ISPOR）价值之花吗？ （注：这里“xit”不太明确准确含义，可能是特定语境下的特定指代，暂按原样翻译）
J Comp Eff Res. 2024 Sep;13(9):e240083. doi: 10.57264/cer-2024-0083. Epub 2024 Jul 19.
5
Incorporating Real Option Value in Valuing Innovation: A Way Forward.将实物期权价值纳入创新估值：一种前进的方式。
Pharmacoeconomics. 2024 Jul;42(Suppl 2):199-210. doi: 10.1007/s40273-024-01352-4. Epub 2024 Feb 4.
6
Reconstructing the value puzzle in health technology assessment: a pragmatic review to determine which modelling methods can account for additional value elements.重构卫生技术评估中的价值难题：一项务实性综述，以确定哪些建模方法能够涵盖额外的价值要素。
Front Pharmacol. 2023 Jul 13;14:1197259. doi: 10.3389/fphar.2023.1197259. eCollection 2023.
7
A review of HTA guidelines on societal and novel value elements.关于 HTA 指南中社会和新颖价值要素的综述。
Int J Technol Assess Health Care. 2023 May 25;39(1):e31. doi: 10.1017/S026646232300017X.
8
Framework for Patient Experience Value Elements in Rare Disease: A Case Study Demonstrating the Applicability of Combined Qualitative and Quantitative Methods.罕见病患者体验价值要素框架：一项展示定性和定量方法相结合适用性的案例研究
Pharmacoecon Open. 2023 Mar;7(2):217-228. doi: 10.1007/s41669-022-00376-w. Epub 2022 Nov 1.
9
Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine.个性化医学经济评估的协调与改进指南。
Pharmacoeconomics. 2021 Jul;39(7):771-788. doi: 10.1007/s40273-021-01010-z. Epub 2021 Apr 16.
10
Assessing potential cures: are there distinctive elements of value beyond health gain?评估潜在的治疗方法：除了健康收益之外，是否存在独特的价值要素？
J Comp Eff Res. 2021 Mar 5;10(4):255-65. doi: 10.2217/cer-2020-0190.
本文引用的文献
1
Augmenting Cost-Effectiveness Analysis Will Not Improve Affordability.增加成本效益分析并不能提高可负担性。
J Manag Care Spec Pharm. 2020 Apr;26(4):407-408. doi: 10.18553/jmcp.2020.26.4.407.
2
The Value of Diagnostic Testing in Personalized Medicine.诊断检测在个性化医疗中的价值。
Forum Health Econ Policy. 2013 Sep 1;16(2):S87-S99. doi: 10.1515/fhep-2013-0023.
3
Quantifying the Value of Personalized Medicines: Evidence from COX-2 Inhibitors.量化个性化药物的价值：来自COX-2抑制剂的证据。
Forum Health Econ Policy. 2013 Jan 1;16(1):101-122. doi: 10.1515/fhep-2013-0005.
4
The Option Value of Innovation.创新的期权价值。
Forum Health Econ Policy. 2012 Apr 18;15(2):/j/fhep.2012.15.issue-2/1558-9544.1306/1558-9544.1306.xml. doi: 10.1515/1558-9544.1306.
5
How Does Option Value Affect the Potential Cost-Effectiveness of a Treatment? The Case of Ipilimumab for Metastatic Melanoma.选择价值如何影响治疗的潜在成本效益？以依匹单抗治疗转移性黑色素瘤为例。
Value Health. 2019 Jul;22(7):777-784. doi: 10.1016/j.jval.2019.02.002. Epub 2019 May 17.
6
Do cancer treatments have option value? Real-world evidence from metastatic melanoma.癌症治疗是否具有期权价值？转移性黑色素瘤的真实世界证据。
Health Econ. 2019 Jul;28(7):855-867. doi: 10.1002/hec.3899.
7
The Option Value of Innovative Treatments for Metastatic Melanoma.转移性黑色素瘤创新疗法的期权价值
Forum Health Econ Policy. 2018 Jun 21;21(1):/j/fhep.2018.21.issue-1/fhep-2016-0014/fhep-2016-0014.xml. doi: 10.1515/fhep-2016-0014.
8
An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: Does it make a difference?加拿大二线纳武利尤单抗治疗鳞状非小细胞肺癌患者的成本效益分析扩展影响的探索性病例研究：是否有影响？
Health Policy. 2018 Jun;122(6):607-613. doi: 10.1016/j.healthpol.2018.04.008. Epub 2018 Apr 26.
9
A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7].一种用于美国价值评估框架的卫生经济学方法——国际药物经济学与结果研究协会（ISPOR）特别工作组报告的总结与建议[7]
Value Health. 2018 Feb;21(2):161-165. doi: 10.1016/j.jval.2017.12.009.
10
Approaches to Aggregation and Decision Making-A Health Economics Approach: An ISPOR Special Task Force Report [5].汇总与决策方法——一种卫生经济学方法：一份ISPOR特别工作组报告[5]
Value Health. 2018 Feb;21(2):146-154. doi: 10.1016/j.jval.2017.12.010.
Zotero 插件